Sandoz: UBS upgrades stock

(CercleFinance.com) - UBS has upgraded its recommendation on Sandoz from 'neutral' to 'buy', with a target price raised from 29.
1 CHF to 36 CHF, with its new TP offering 23% upside potential for the Swiss generics and biosimilars group.

In the summary of its research note, the broker says that it is more positive about access to biosimilars in the US, and highlights recent performances which are not reflected in the current undemanding valuation.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.